Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Shareholders' Deficit - Unaudited - USD ($) $ in Thousands	Total	Redeemable Noncontrolling Interest [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Gain [Member]	Accumulated Deficit [Member]	Common Class A [Member]	Class A Ordinary Shares [Member] Common Stock [Member]	Class B Ordinary Shares [Member] Common Stock [Member]
Beginning balance at Dec. 31, 2023	$ (1,103,396)	$ 1,494,732	$ 36,114	$ 130	$ (1,139,663)		$ 6	$ 17
Beginning balance, shares at Dec. 31, 2023							59,880,347	168,297,916
Equity-based compensation	18,559	3,865	18,559
Issuance of Class A common stock, shares							62,087,817
Issuance of Class A common stock, value	144,325		144,319				$ 6
Vesting of Class B restricted stock rights, shares								1,395,202
Exchange of Class B common stock for Class A common stock	15,357
Exchange of Class B common stock for Class A common stock, value	15,356	(15,356)	15,356				$ 1	$ (1)
Exchange of Class B common stock for Class A common stock, shares							5,951,442	(5,951,442)
Exercise of stock options, Shares							668
Impact of equity transactions on redeemable noncontrolling interest	(14,839)	14,839	(14,839)
Unrealized income on marketable securities	191	44		191
Net loss and comprehensive loss attributable to noncontrolling interest	74,944	(74,944)
Net Income (Loss)	(39,908)				(39,908)	$ (39,908)
Ending balance at Sep. 30, 2024	(979,712)	1,423,180	199,509	(321)	(1,179,571)		$ 13	$ 16
Ending balance, shares at Sep. 30, 2024							127,920,274	163,741,676
Beginning balance at Jun. 30, 2024	(972,371)	1,444,737	189,267	(6)	(1,161,661)		$ 13	$ 16
Beginning balance, shares at Jun. 30, 2024							125,856,877	163,817,953
Equity-based compensation	6,084	851	6,084
Issuance of Class A common stock, shares							1,868,891
Issuance of Class A common stock, value	4,470		4,470
Vesting of Class B restricted stock rights, shares								117,842
Exchange of Class B common stock for Class A common stock, value	454	(454)	454
Exchange of Class B common stock for Class A common stock, shares							194,119	(194,119)
Exercise of stock options, Shares							387
Impact of equity transactions on redeemable noncontrolling interest	(766)	766	(766)
Unrealized income on marketable securities	327	423		327
Net loss and comprehensive loss attributable to noncontrolling interest	23,143	(23,143)
Net Income (Loss)	(17,910)				(17,910)	(17,910)
Ending balance at Sep. 30, 2024	(979,712)	1,423,180	199,509	(321)	(1,179,571)		$ 13	$ 16
Ending balance, shares at Sep. 30, 2024							127,920,274	163,741,676
Beginning balance at Dec. 31, 2024	(994,954)	1,396,591	205,736	130	(1,200,849)		$ 13	$ 16
Beginning balance, shares at Dec. 31, 2024							128,054,417	163,693,707
Equity-based compensation	17,354	2,279	17,354
Issuance of Class A common stock, shares							1,989,147
Issuance of Class A common stock, value	7,103		7,102				$ 1
Vesting of Class B restricted stock rights, shares								959,764
Exchange of Class B common stock for Class A common stock	5,252
Exchange of Class B common stock for Class A common stock, value	5,252	(5,252)	5,252
Exchange of Class B common stock for Class A common stock, shares							5,364,540	(5,364,540)
Exercise of stock options, Shares							569,841
Exercise of stock options	854		854
Impact of equity transactions on redeemable noncontrolling interest	6,182	(6,182)	6,182
Unrealized income on marketable securities	(56)	(73)		(56)
Net loss and comprehensive loss attributable to noncontrolling interest	61,005	61,005
Net Income (Loss)	(49,755)				(49,755)	(49,755)
Ending balance at Sep. 30, 2025	(1,008,020)	1,326,358	242,480	74	(1,250,604)		$ 14	$ 16
Ending balance, shares at Sep. 30, 2025							135,977,945	159,288,931
Beginning balance at Jun. 30, 2025	(1,002,500)	1,341,953	231,576	30	(1,234,135)		$ 13	$ 16
Beginning balance, shares at Jun. 30, 2025							133,418,957	159,288,931
Equity-based compensation	5,936	740	5,936
Issuance of Class A common stock, shares							1,989,147
Issuance of Class A common stock, value	7,103		7,102				$ 1
Exercise of stock options, Shares							569,841
Exercise of stock options	854		854
Impact of equity transactions on redeemable noncontrolling interest	(2,988)	2,988	(2,988)
Unrealized income on marketable securities	44	51		44
Net loss and comprehensive loss attributable to noncontrolling interest	19,374	(19,374)
Net Income (Loss)	(16,469)				(16,469)	$ (16,469)
Ending balance at Sep. 30, 2025	$ (1,008,020)	$ 1,326,358	$ 242,480	$ 74	$ (1,250,604)		$ 14	$ 16
Ending balance, shares at Sep. 30, 2025							135,977,945	159,288,931

PROKIDNEY CORP. 10-Q